An Anticancer Pt IV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.

Dual- or multi-action Pt-IV prodrugs represent a new generation of platinum anticancer drugs. The important property of these Pt-IV prodrugs is that their antitumor action combines several different mechanisms owing to the presence of biologically active axial ligands. This work describes the synthesis and some biological properties of a triple-action prodrug that releases in cancer cells cisplatin and two different epigenetically acting moieties, octanoate and phenylbutyrate. It is demonstrated, with the aid of modern methods of molecular and cellular biology and pharmacology, that the presence of three different functionalities in a single molecule of the Pt-IV prodrug results in a selective and high potency in tumor cells including those resistant to cisplatin [the IC50 values in the screened malignant cell lines ranged from as low as 9nm (HCT-116) to 74nm (MDA-MB-231)]. It is also demonstrated that cellular activation of the Pt-IV prodrug results in covalent modification of DNA through the release of the platinum moiety accompanied by inhibition of the activity of histone deacetylases caused by phenylbutyrate and by global hypermethylation of DNA by octanoate. Thus, the Pt-IV prodrug introduced in this study acts as a true multi-action prodrug, which is over two orders of magnitude more active than clinically used cisplatin, in both 2D monolayer culture and 3D spheroid cancer cells.